Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00300443

Enrollment

561

Registered

2006-03-09

Start date

2005-12-31

Completion date

2007-06-30

Last updated

2011-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension

Brief summary

The purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular hypertension

Interventions

DRUGbimatoprost

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of glaucoma or ocular hypertension in both eyes * Patient requires IOP-lowering drug in both eyes

Exclusion criteria

* Uncontrolled medical conditions * Ocular seasonal allergies within the past 2 years

Design outcomes

Primary

Measure	Time frame
Lowering intraocular pressure (IOP)	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026